Launch week offerEnds in00h00m00s

annual Promonthly Pro

Kimmo Taari

University of Helsinki

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (23)

Collaborators (10)

Teemu J. Murtola

Reija Autio

University of Tampere

Giuseppe Gorini

Institute for Cancer Research, Prevention and Clinical Network-ISPRO

Anssi Auvinen

University of Tampere

Tuomas Mirtti

University of Helsinki

Aino Siltari

University of Helsinki

Luis Llanes

Associated Professor

Universidad Francisco de Vitoria

Sebastiaan Remmers

Erasmus University Rotterdam

Antti Rannikko

University of Helsinki

Jani Raitanen

University of Tampere

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Kimmo Taari

Research Interests

Make your next move.

Explore related searches

Articles (23)

Collaborators (10)

Teemu J. Murtola

Reija Autio

Giuseppe Gorini

Anssi Auvinen

Tuomas Mirtti

Aino Siltari

Luis Llanes

Sebastiaan Remmers

Antti Rannikko

Jani Raitanen

Make your next move.

Kimmo Taari

Research Interests

Make your next move.

Explore related searches

Articles (23)

Cancer detection in the European Randomised Study of Screening for Prostate Cancer (ERSPC)

Do differences in secondary treatment explain mortality impact of prostate cancer screening?

Long-term Risk of Prostate Cancer Mortality Among Men with Baseline Prostate-specific Antigen Below 3 ng/ml

Risk factors for low-risk prostate cancer

SNP genotypes in CYP2C9 and VKORC1 genes do not affect prostate cancer or cancer mortality among warfarin users in Finnish prostate cancer patients

Time Dependence of Outcomes in the SPCG-4 Randomized Trial Comparing Radical Prostatectomy and Watchful Waiting in Early Prostate Cancer

Expected impact of MRI-targeted biopsy interreader variability among uropathologists on ProScreen prostate cancer screening trial

Prostate Cancer Screening with PSA, Kallikrein Panel, and MRI

Allopurinol and prostate cancer survival in a Finnish population-based cohort

Screening history and risk of death from prostate cancer

Which men benefit from prostate cancer screening? Prostate cancer mortality by subgroup in the European Randomised Study of Screening for Prostate Cancer

Antidiabetic drugs, glycemic control and risk of benign prostatic hyperplasia

Prostate cancer incidence in men with prostate-specific antigen below 3 ng/mL

Statin use and outcomes of oncological treatment for castration-resistant prostate cancer

Testosterone replacement therapy is not associated with increased prostate cancer incidence, prostate cancer-specific, or cardiovascular disease-specific mortality in Finnish men

Population‐based randomized trial of screening for clinically significant prostate cancer ProScreen: a pilot study

Anti-epileptic drugs and prostate cancer-specific mortality compared to non-users of anti-epileptic drugs in the Finnish Randomized Study of Screening for Prostate Cancer

Inverse Association between Statin Use and Cancer Mortality Relates to Cholesterol Level

Outcomes of Screening for Prostate Cancer Among Men Who Use Statins

Estimating the rate of overdiagnosis with prostate cancer screening

Digital rectal examination in prostate cancer screening at PSA level 3.0-3.9 ng/ml

Prostate cancer prognosis after initiation of androgen deprivation therapy among statin users. A population-based cohort study

Antiepileptic drugs and prostate cancer risk in the Finnish Randomized Study of Screening for Prostate Cancer

Collaborators (10)

Teemu J. Murtola

Reija Autio

Giuseppe Gorini

Anssi Auvinen

Tuomas Mirtti

Aino Siltari

Luis Llanes

Sebastiaan Remmers

Antti Rannikko

Jani Raitanen

Make your next move.